Aerovate Therapeutics Inc (AVTE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has a cash flow conversion efficiency ratio of -0.032x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($75.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aerovate Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Aerovate Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Aerovate Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Aerovate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aerovate Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hennessy Ad
NASDAQ:HNNA
|
0.023x |
|
Wellpool Co Ltd
TWO:8424
|
0.114x |
|
Heranba Industries Limited
NSE:HERANBA
|
0.015x |
|
Thai Mitsuwa Public Company Limited
BK:TMW
|
0.023x |
|
District Metals Corp
V:DMX
|
-0.027x |
|
Asetek A/S
F:A31
|
0.018x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
|
Energous Corporation
NASDAQ:WATT
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Aerovate Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | -126.98% |
| 2020-12-31 | $-13.34 Million | $-7.86 Million | 0.589x | -22.85% |
| 2019-12-31 | $-3.64 Million | $-2.78 Million | 0.763x | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.